Skip to content

Application of sarcubatroxtan in the treatment of chronic heart failure in Hemodialysis patients: a prospective open label single center cohort study

Application of sarcubatroxtan in the treatment of chronic heart failure in Hemodialysis patients: a prospective open label single center cohort study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040750
Enrollment
Unknown
Registered
2020-12-08
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure in hemodialysis patients

Interventions

Sponsors

Blood Purification Center of Peking University International Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) >=18 years old; those who have the ability to provide informed consent after explaining the proposed study; (2) symptoms or signs of chronic heart failure LVEF=150 (or >=600pg/mL), or >=100 (or >=400pg/mL), with HFrEF hospitalized within 12 months; (4) the follow-up can be completed for 3 months.

Exclusion criteria

Exclusion criteria: (1) Acute decompensated heart failure; (2) severe history of lung disease; (3) Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty, and severe complications of other organs were present within 3 months of screening; (4) History of neuroedema; (5) other situations that the researchers think are not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;LVEF: left ventricular ejection fraction;E/E';

Countries

China

Contacts

Public ContactDongLiang Zhang

Blood Purification Center of Peking University International Hospital

zhangdongliang@pkuih.edu.cn+86 13661310616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026